FMP
Stealth BioTherapeutics Corp
MITO
NASDAQ
Inactive Equity
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
0.32 USD
0 (0%)
Latest MITO News
PRNewsWire
May 6, 2024
Stealth BioTherapeutics to Present at JMP Citizens Life Sciences Conference
NEEDHAM, Mass. , May 6, 2024 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that Reenie McCarthy, Stealth's Chief Executive Officer, will participate in a fireside chat at the JMP Citizens Life Sciences Conference in New York on Monday, May 13 at 2:30 p.m.
PennyStocks
Jun 8, 2022
Good Penny Stocks to Buy Today? 3 to Watch Right Now
Here are three penny stocks to watch right now The post Good Penny Stocks to Buy Today? 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Benzinga
Jun 8, 2022
Why Stealth BioTherapeutics Shares Are Surging Today?
Stealth BioTherapeutics Corp (NASDAQ: MITO) presented new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology. TDP-43 pathology plays a significant role in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
PennyStocks
May 10, 2022
What to Know About Buying Penny Stocks on May 10th
Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 10th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Benzinga
May 2, 2022
Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study
Stealth BioTherapeutics Corp (NASDAQ: MITO) has announced topline data from its Phase 2 ReCLAIM-2 trial evaluating elamipretide in geographic atrophy (GA) secondary to dry age-related macular degeneration. Although the trial did not meet its primary endpoints, a key secondary.
PRNewsWire
Mar 9, 2022
Stealth BioTherapeutics to Present at Upcoming March Investor Conferences
BOSTON , March 9, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at three upcoming investor conferences in March: Oppenheimer 32nd Annual Healthcare Conference. Pre-recorded presentation available for on-demand viewing starting on Tuesday, March 15 at 4:40 ...
PRNewsWire
Feb 22, 2022
Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit
BOSTON, Feb. 22, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the virtual Mitochondria-Targeted Drug Development Summit on Thursday, February 24, 2022 at 9:00 a.m. ET. Reenie McCarthy's presentation is titled, "Mitochondria as a Target for Ophthalmic D...
PRNewsWire
Jan 4, 2022
Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
BOSTON, Jan. 4, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright BioConnect Virtual Conference taking place from January 10-13, 2022.
Seeking Alpha
Nov 11, 2021
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call Transcript
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call Transcript
Benzinga
Oct 20, 2021
Stealth Bio Stock Falls On FDA Refusal to File Letter For Barth Syndrome Candidate
Stealth BioTherapeutics Corp (NASDAQ: MITO) has received a Refusal to File letter from the FDA regarding its marketing application for elamipretide, a mitochondria-targeted therapy for Barth syndrome. Barth syndrome is an ultra-rare genetic condition characterized by cardiac abnormalities often leading to heart failure and reduced life expectancy, recurrent infections, muscle weakness, and delayed growth.
